Tarsus Pharmaceuticals beats Q4 revenue estimates

Tarsus Pharmaceuticals

23/02/2026 21:19

Overview

Pharmaceutical firm's Q4 revenue beat analysts' expectations

Net product sales of XDEMVY increased over 150% yr/yr to $451.4 mln

Company initiated Phase 2 trial for TP-04 in ocular rosacea

Outlook

Company expects XDEMVY peak sales potential to exceed $2 bln

Tarsus plans Phase 2 trial of TP-05 for Lyme disease prevention in Q2 2026

Company expects potential approval for XDEMVY in Greater China in 2026

Result Drivers

XDEMVY SALES GROWTH - Tarsus attributed over 150% yr/yr increase in XDEMVY sales to broad access and changes in physician treatment practices

DTC CAMPAIGN SUCCESS - Direct-to-consumer campaign increased awareness of Demodex blepharitis, contributing to sales growth

Company press release: ID:nGNX8T3P10

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$151.67 mln
$144.57 mln (6 Analysts)
Q4 EPS
-$0.20
Q4 Net Income
-$8.37 mln
Q4 Basic EPS
-$0.20


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Tarsus Pharmaceuticals Inc is $88.00, about 32.1% above its February 20 closing price of $66.61

The stock recently traded at 39 times the next 12-month earnings vs. a P/E of 87 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)